The Harvard scientist acting as ATAI's treasure trove launches a new psychedelics firm focused on drug 'analogues'
A former Harvard and NIH scientist is returning to the psychedelics field with a new biotech after selling his last effort to the buzzy ATAI Life Sciences.
Gilgamesh Pharmaceuticals completed its $27 million Series A on Thursday, the company announced, with plans to use the cash to prep four programs for INDs and continue expanding its leadership team. The biotech is led by CEO Jonathan Sporn, and it’s not his first rodeo in psychedelics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.